Kalp Sorunları ve İlaç Kaynaklı Kardiyak Toksite
Özet
Kanser tedavisinde kalp yetmezliği, aritmi, hipertansiyon gibi kemoterapiye bağlı kardiyotoksisite zorluluğa yol açan en önemli sorunların başında gelir. Ayrıca artan kanser sağkalım oranları ile birlikte hastaların uzun vade de kardiyovasküler sağlığı önem kazanmıştır.Doksorubisin,epirubisin gibi antrasiklin grubu kümülatif doza bağımlı irreversible kardiyotoksisiteye neden olurken, trastuzumab reversible kardiyotoksisite yapar. Floropirimidin grubunda ise en sık kardiyak yan etki olarak akut koroner spasm görülmektedir. Hastalar tedavi başlamadan kardiyovasküler risk açısından değerlendirilmeli, tedavi süresince takipleri yapılmalıdır. Kardiyotoksisite gelişmesi durumunda klavuz önerileri doğrultusunda tedavisi düzenlenmelidir.
In cancer treatment, cardiotoxicity due to chemotherapy such as heart failure, arrhythmia, hypertension are among the most important problems that cause difficulties. In addition, with the increasing cancer survival rates, the long-term cardiovascular health of patients has gained importance. While the anthracycline group such as doxorubicin and epirubicin causes irreversible cardiotoxicity depending on the cumulative dose, trastuzumab causes reversible cardiotoxicity. In the fluoropyrimidine group, the most common cardiac side effect is acute coronary spasm. Patients should be evaluated for cardiovascular risk before starting treatment and should be followed up during treatment. In case of cardiotoxicity, treatment should be arranged in accordance with guideline recommendations.
Referanslar
Nagy A, Börzsei D, Hoffmann A, et al. A comprehensive overview on chemotherapy-induced cardiotoxicity: insights into the underlying inflammatory and oxidative mechanisms. Cardiovasc Drugs Ther 2024.
Gorini S, De Angelis A, Berrino L, et al. Chemotherapeutic drugs and mitochondrial dysfunction: focus on doxorubicin, trastuzumab, and sunitinib. Oxid Med Cell Longev 2018; 2018:7582730.
Sara JD, Kaur J, Khodadadi R, et al. 5-fluorouracil and cardiotoxicity: a review. Ther Adv Med Oncol 2018;10:1758835918780140.
More LA, Lane S, Asnani A. 5-FU cardiotoxicity: vasospasm, myocarditis, and sudden death. Curr Cardiol Rep 2021;23:17.
Al-Taher AY, Morsy MA, Rifaai RA, et al. Paeonol attenuates methotrexate-induced cardiac toxicity in rats by inhibiting oxidative stress and suppressing TLR4-induced NF-κB inflammatory pathway. Mediators Inflamm 2020; 2020:8641026.
Michel G Khouri 1, Pamela S Douglas, John R Mackey, Miguel Martin, Jessica M Scott, Marielle Scherrer-Crosbie, Lee W Jones. Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues Circulation. 2012 Dec;126(23):2749-63.
Tan TC, Neilan TG, Francis S, Plana JC, Scherrer-Crosbie M, Anthracycline-Induced Cardiomyopathy in Adults. Compr Physiol. 2015 Jul;5(3):1517-40.
Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, Civelli M, Lamantia G, Colombo N, Curigliano G, Fiorentini C, Cipolla CM, Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy,Circulation 2015 Jun;131(22):1981-8. Epub 2015 May 6.
Swain SM,Whaley FS,Ewer MS ,Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97(11):2869.
Zheng H,It Is Time to Abandon the Use of Body Surface Area Derived From a 100-Year-Old Formula,Am J Med. 2022;135(9):e308. Epub 2022 Apr 23.
Armstrong GT, Oeffinger KC, Chen Y, Kawashima T, Yasui Y, Leisenring W, Stovall M, Chow EJ, Sklar CA, Mulrooney DA, Mertens AC, Border W, Durand JB, Robison LL, Meacham LR,Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. J Clin Oncol. 2013;31(29):3673. Epub 2013 Sep 3.
Smith LA, Cornelius VR, Plummer CJ, Levitt G, Verrill M, Canney P, Jones A,Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer. 2010;10:337. Epub 2010 Jun 29.
Feijen EAM, Leisenring WM, Stratton KL, Ness KK, van der Pal HJH, van Dalen EC, Armstrong GT, Aune GJ, Green DM, Hudson MM, Loonen J, Oeffinger KC, Robison LL, Yasui Y, Kremer LCM, Chow EJ ,Derivation of Anthracycline and Anthraquinone Equivalence Ratios to Doxorubicin for Late-Onset Cardiotoxicity. JAMA Oncol. 2019;5(6):864.
Bhatia S ,Genetics of Anthracycline Cardiomyopathy in Cancer Survivors: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol. 2020;2(4):539. Epub 2020 Dec 22.
Legha SS, Benjamin RS, Mackay B, Yap HY, Wallace S, Ewer M, Blumenschein GR, Freireich EJ Adriamycin, therapy by continuous intravenous infusion in patients with metastatic breast cancer. Cancer. 1982 May;49(9):1762-6.
Armenian SH, Lacchetti C, Barac A, Carver J, Constine LS, Denduluri N, Dent S, Douglas PS, Durand JB, Ewer M, Fabian C, Hudson M, Jessup M, Jones LW, Ky B, Mayer EL, Moslehi J, Oeffinger K, Ray K, Ruddy K, Lenihan D,Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017;35(8):893. Epub 2016 Dec 5.
Abdel-Qadir H, Ong G, Fazelzad R, Amir E, Lee DS, Thavendiranathan P, Tomlinson G,Interventions for preventing cardiomyopathy due to anthracyclines: a Bayesian network meta-analysis. Ann Oncol. 2017;28(3):628.
Labianca R, Beretta G, Clerici M, Fraschini P, Luporini G Cardiac toxicity of 5-fluorouracil: a study on 1083 patients. Tumori. 1982;68(6):505.
Rozenman Y, Gurewich J, Gotsman MS Myocardial ischemia induced by topical use of 5-fluorouracil. Int J Cardiol. 1995;49(3):282.
Meyer CC, Calis KA, Burke LB, Walawander CA, Grasela TH,Symptomatic cardiotoxicity associated with 5-fluorouracil.Pharmacotherapy. 1997 Jul-Aug;17(4):729-36.
Kosmas C, Kallistratos MS, Kopterides P, Syrios J, Skopelitis H, Mylonakis N, Karabelis A,Tsavari N ,Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study.J Cancer Res Clin Oncol. 2008 Jan;134(1):75-82. Epub 2007 Jul 17.
Saif MW,Shah MM,Shah AR ,Fluoropyrimidine-associated cardiotoxicity: revisited. Expert Opin Drug Saf. 2009;8(2):191.
Shahrokni A, Rajebi MR, Saif MW ,Toxicity and efficacy of 5-fluorouracil and capecitabine in a patient with TYMS gene polymorphism: A challenge or a dilemma? ,Clin Colorectal Cancer. 2009;8(4):231.
Morel A, Boisdron-Celle M, Fey L, Soulie P, Craipeau MC, Traore S, Gamelin E, Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol Cancer Ther. 2006;5(11):2895.
de Forni M, Malet-Martino MC, Jaillais P, Shubinski RE, Bachaud JM, Lemaire L, Canal P, Chevreau C, CarriéD, SouliéP Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. J Clin Oncol. 1992;10(11):1795.
Becker K, Erckenbrecht JF, Häussinger D, Frieling T,Cardiotoxicity of the antiproliferative compound fluorouracil,Drugs. 1999 Apr;57(4):475-84.
Cianci G, Morelli MF, Cannita K, Morese R, Ricevuto E, Di Rocco ZC, Porzio G, Lanfiuti Baldi P, Ficorella C ,Prophylactic options in patients with 5-fluorouracil-associated cardiotoxicity.Br J Cancer. 2003;88(10):1507.
Chakrabarti S, Sara J, Lobo R, Eiring R, Finnes H, Mitchell J, Hartgers M, Okano A, Halfdanarson T, Grothey A,Bolus 5-fluorouracil (5-FU) In Combination With Oxaliplatin Is Safe and Well Tolerated in Patients Who Experienced Coronary Vasospasm With Infusional 5-FU or Capecitabine. Clin Colorectal Cancer. 2019;18(1):52. Epub 2018 Oct 10.
Frickhofen N, Beck FJ, Jung B, Fuhr HG, Andrasch H, Sigmund M Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil. Ann Oncol. 2002;13(5):797.
Ma WW, Saif MW, El-Rayes BF, Fakih MG, Cartwright TH, Posey JA, King TR, von Borstel RW, Bamat MK ,Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity.Cancer. 2017;123(2):345. Epub 2016 Sep 13.
Cote GM, Sawyer DB, Chabner B,ERBB2 inhibition and heart failure. N Engl J Med. 2012 Nov;367(22):2150-3.
Keefe DL,Trastuzumab-associated cardiotoxicity Cancer 2002;95(7):1952
Ewer MS, Vooletich MT, Durand JB, Woods ML, Davis JR, Valero V, Lenihan DJ Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment.J Clin Oncol. 2005;23(31):7820.
Russell SD, Blackwell KL, Lawrence J, Pippen JE Jr, Roe MT, Wood F, Paton V, Holmgren E, Mahaffey KW ,Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. J Clin Oncol. 2010;28(21):3416. Epub 2010 Jun 7.
35.. Halyard MY, Pisansky TM, Dueck AC, Suman V, Pierce L, Solin L, Marks L, Davidson N, Martino S, Kaufman P, Kutteh L, Dakhil SR, Perez EA,Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831. J Clin Oncol. 2009;27(16):2638. Epub 2009 Apr 6.
Serrano C, Cortés J, De Mattos-Arruda L, Bellet M, Gómez P, Saura C, Pérez J, Vidal M, Muñoz-Couselo E, Carreras MJ, Sánchez-OlléG, Tabernero J, Baselga J, Di Cosimo S Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors. Ann Oncol. 2012;23(4):897.
Guglin M, Krischer J, Tamura R, Fink A, Bello-Matricaria L, McCaskill-Stevens W, Munster PN Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer. J Am Coll Cardiol. 2019;73(22):2859.
Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N ,Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673.
Arbuck SG, Strauss H, Rowinsky E, Christian M, Suffness M, Adams J, Oakes M, McGuire W, Reed E, Gibbs H A reassessment of cardiac toxicity associated with Taxol. J Natl Cancer Inst Monogr. 1993;
Gottdiener JS, Appelbaum FR, Ferrans VJ, Deisseroth A, Ziegler J ,Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med. 1981;141(6):758.
Tomirotti M, Riundi R, Pulici S, Ungaro A, Pedretti D, Villa S, Scanni A ,Ischemic cardiopathy from cis-diamminedichloroplatinum (CDDP). Tumori. 1984;70(3):235.
Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia FM, Pujade-Lauraine E, Park YC, Parekh TV, Poveda AM Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis. Eur J Cancer. 2012 Oct;48(15):2361-8. Epub 2012 Apr 26.
House KW, Simon SR, Pugh RP Chemotherapy-induced myocardial infarction in a young man with Hodgkin's disease. Clin Cardiol. 1992;15(2):122.
Ewer MS, Tekumalla SH, Walding A, Atuah KN Cardiac Safety of Osimertinib: A Review of Data. J Clin Oncol. 2021;39(4):328. Epub 2020 Dec 23.
